Sibeliuma Range 5mg/10mg Tablet

    Sibeliuma Range 5mg/10mg Tablet

    S2
    PDF Leaflet Revision Date: 12 May 2022


    Clinical Summary

    Quick overview from the medicine insert

    Indication

    Prophylaxis of migraine and symptomatic treatment of vestibular vertigo.

    Dosage (summary)

    Adults: 10 mg at night; Elderly: 5 mg daily.

    Special Populations

    • Elderly
    • Paediatrics (6-17 years)

    Pregnancy & Breastfeeding

    Safety in pregnancy not established; contraindicated in breastfeeding.

    Key Drug Interactions

    • Alcohol
    • Phenothiazines
    • Hepatic enzyme inducers

    Contraindications

    • Hypersensitivity to flunarizine
    • History of depressive illness
    • Parkinson's disease

    Common side effects

    • Somnolence
    • Depression
    • Increased weight
    • Increased appetite

    Counselling Points

    • Take at night
    • Do not exceed recommended dose
    • Report any depressive symptoms

    Serious warnings

    • May cause extrapyramidal symptoms
    • Monitor for depressive symptoms
    Important Disclaimer

    The Sibeliuma Range 5mg/10mg Tablet professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

    Healthcare Professionals Only

    This content is for registered healthcare professionals

    Sign in or create a free account to read the full package insert.

    Free for HPCSA-registered professionals. Powered by Medinsert.

    Successfully Stashed! 💊

    This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

    View My Favourites
    WhatsApp Email LinkedIn